{"id":"NCT01655381","sponsor":"Hoffmann-La Roche","briefTitle":"A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis","officialTitle":"A Multicenter, Open-label, Single Arm, Long-term Extension Study of WA19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-04","primaryCompletion":"2015-07","completion":"2015-07","firstPosted":"2012-08-01","resultsPosted":"2017-01-31","lastUpdate":"2017-01-31"},"enrollment":15,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Tocilizumab","otherNames":["RoActemra®","Actemra®"]}],"arms":[{"label":"Tocilizumab","type":"EXPERIMENTAL"}],"summary":"This open-label, single arm, multicenter long-term extension study will evaluate the safety and efficacy of tocilizumab (RoActemra/Actemra) in participants with moderate to severe rheumatoid arthritis who have completed the 104-week WA19926 core study. Eligible participants will receive tocilizumab 8 mg/kg intravenously every 4 weeks for up to 104 weeks.","primaryOutcome":{"measure":"Percentage of Participants With Any Adverse Event (AE)","timeFrame":"Up to 160 weeks","effectByArm":[{"arm":"Tocilizumab","deltaMin":93.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":12},"locations":{"siteCount":6,"countries":["France"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":15},"commonTop":["Bronchitis","Back pain","Gastroenteritis","Nasopharyngitis","Asthenia"]}}